Abstract
A number of different approaches are under development for treating nonexudative manifestations of age-related macular degeneration (AMD). Some interventions target specific pathways that are believed to play a role in AMD pathogenesis, e.g. oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. β-amyloid accumulation), impaired choroidal blood flow, and apoptosis. In principle, these therapies can be combined ('combination therapy'), which may lead to synergistic effects that include better visual outcome, less likelihood for 'escape' (i.e. drug resistance), and less frequent treatment
| Original language | English |
|---|---|
| Pages (from-to) | 107-115 |
| Number of pages | 9 |
| Journal | Ophthalmic Research |
| Volume | 52 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jan 1 2014 |
Fingerprint
Keywords
- Age-related macular degeneration
- Drugs
- Drusen
- Geographic atrophy
- Neurotrophic factors
- Oxidative damage
- Pathway
- Stem cells
- Treatment
- Visual cycle
ASJC Scopus subject areas
- Ophthalmology
- Sensory Systems
- Cellular and Molecular Neuroscience
Cite this
Treatment of dry age-related macular degeneration. / Querques, Giuseppe; Rosenfeld, Philip J; Cavallero, Edoardo; Borrelli, Enrico; Corvi, Federico; Querques, Lea; Bandello, Francesco M.; Zarbin, Marco A.
In: Ophthalmic Research, Vol. 52, No. 3, 01.01.2014, p. 107-115.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of dry age-related macular degeneration
AU - Querques, Giuseppe
AU - Rosenfeld, Philip J
AU - Cavallero, Edoardo
AU - Borrelli, Enrico
AU - Corvi, Federico
AU - Querques, Lea
AU - Bandello, Francesco M.
AU - Zarbin, Marco A.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - A number of different approaches are under development for treating nonexudative manifestations of age-related macular degeneration (AMD). Some interventions target specific pathways that are believed to play a role in AMD pathogenesis, e.g. oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. β-amyloid accumulation), impaired choroidal blood flow, and apoptosis. In principle, these therapies can be combined ('combination therapy'), which may lead to synergistic effects that include better visual outcome, less likelihood for 'escape' (i.e. drug resistance), and less frequent treatment
AB - A number of different approaches are under development for treating nonexudative manifestations of age-related macular degeneration (AMD). Some interventions target specific pathways that are believed to play a role in AMD pathogenesis, e.g. oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. β-amyloid accumulation), impaired choroidal blood flow, and apoptosis. In principle, these therapies can be combined ('combination therapy'), which may lead to synergistic effects that include better visual outcome, less likelihood for 'escape' (i.e. drug resistance), and less frequent treatment
KW - Age-related macular degeneration
KW - Drugs
KW - Drusen
KW - Geographic atrophy
KW - Neurotrophic factors
KW - Oxidative damage
KW - Pathway
KW - Stem cells
KW - Treatment
KW - Visual cycle
UR - http://www.scopus.com/inward/record.url?scp=84910643156&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84910643156&partnerID=8YFLogxK
U2 - 10.1159/000363187
DO - 10.1159/000363187
M3 - Article
VL - 52
SP - 107
EP - 115
JO - Ophthalmic Research
JF - Ophthalmic Research
SN - 0030-3747
IS - 3
ER -